Helen Thackray, MD, Pediatrics, Rockville, MD, Holy Cross Hospital

HelenMThackrayMDFAAP

Pediatrics Rockville, MD

Medical Genetics

Chief Medical Officer; Senior Vice President, Clinical Development

Dr. Thackray is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Thackray's full profile

Already have an account?

Summary

  • Seasoned biotechnology executive with a special interest in novel drug development for rare diseases in both pediatric and adult indications. Expertise in regulatory strategy, international drug development guidelines, and innovative clinical trial design. Experienced in leadership through transition and growth.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterRESIDENCY
  • Children's National Medical Center - George Washington University
    Children's National Medical Center - George Washington UniversityRESIDENCY
  • George Washington University School of Medicine
    George Washington University School of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1999 - 2021
  • DC State Medical License
    DC State Medical License 1996 - 2020
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
    Helen M Thackray, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Ov...
    Helen M Thackray, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Study of Treatment Aiming to Prevent Advanced Breast Cancer’s Spread to Bone Doses 1st Patient
    Study of Treatment Aiming to Prevent Advanced Breast Cancer’s Spread to Bone Doses 1st PatientFebruary 07, 2020
  • First Patient with Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359
    First Patient with Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359January 30, 2020
  • GlycoMimetics to Present Further Analysis of Data from Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting
    GlycoMimetics to Present Further Analysis of Data from Phase 1/2 AML Trial of Uproleselan at 61st ASH MeetingNovember 06, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations